See more : Daegu Department Store Co., Ltd. (006370.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Okasan Securities Group Inc. (8609.T) Income Statement Analysis – Financial Results
- Tay Two Co., Ltd. (7610.T) Income Statement Analysis – Financial Results
- Information Services Corporation (ISV.TO) Income Statement Analysis – Financial Results
- Washington Business Bank (WBZB) Income Statement Analysis – Financial Results
- Union Bankshares, Inc. (UNB) Income Statement Analysis – Financial Results
Johnson & Johnson (JNJ)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B | 71.31B | 67.22B | 65.03B | 61.59B | 61.90B | 63.75B | 61.10B | 53.32B | 50.51B | 47.35B | 41.86B | 36.30B | 33.00B | 29.14B | 27.47B | 23.66B | 22.63B | 21.62B | 18.84B | 15.73B | 14.14B | 13.75B | 12.45B | 11.23B | 9.76B | 9.00B | 8.01B | 7.00B | 6.42B |
| Cost of Revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.35B | 21.69B | 21.54B | 22.75B | 22.34B | 21.66B | 20.36B | 18.79B | 18.45B | 18.51B | 17.75B | 15.06B | 13.95B | 13.42B | 12.18B | 10.45B | 9.54B | 7.35B | 7.00B | 6.19B | 6.09B | 6.01B | 5.38B | 4.58B | 4.17B | 4.12B | 3.71B | 3.46B | 3.07B | 2.90B | 2.60B | 2.35B | 2.34B |
| Gross Profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.10B | 50.21B | 48.54B | 51.59B | 48.97B | 45.57B | 44.67B | 42.80B | 43.45B | 45.24B | 43.34B | 38.27B | 36.56B | 33.93B | 29.69B | 25.85B | 23.47B | 21.79B | 20.47B | 17.47B | 16.54B | 15.61B | 13.46B | 11.16B | 9.96B | 9.64B | 8.74B | 7.77B | 6.69B | 6.10B | 5.41B | 4.65B | 4.08B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.84% | 69.84% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% | 71.76% | 72.38% | 71.65% | 70.91% | 71.22% | 71.11% | 74.79% | 74.53% | 73.83% | 73.11% | 72.21% | 71.46% | 70.92% | 70.48% | 70.06% | 70.19% | 69.17% | 68.58% | 67.77% | 67.52% | 66.37% | 63.50% |
| Research & Development | 15.05B | 14.14B | 14.28B | 12.34B | 11.36B | 10.78B | 10.55B | 9.10B | 9.05B | 8.49B | 8.18B | 7.67B | 7.55B | 6.84B | 7.17B | 7.76B | 7.68B | 7.13B | 6.31B | 5.20B | 4.68B | 3.96B | 3.59B | 2.93B | 2.60B | 2.27B | 2.14B | 0.00 | 0.00 | 1.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.11B | 19.05B | 20.12B | 22.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B | 22.54B | 21.42B | 19.95B | 21.20B | 21.95B | 21.83B | 20.87B | 20.97B | 19.42B | 19.80B | 21.49B | 20.45B | 17.43B | 16.88B | 15.86B | 14.13B | 12.22B | 11.99B | 10.88B | 10.50B | 8.91B | 8.72B | 10.30B | 9.10B | 6.35B | 6.95B | 6.80B | 6.08B | 5.30B | 4.62B | 4.30B | 3.85B | 3.39B | 2.99B |
| Other Expenses | 0.00 | 500.00M | -526.00M | -2.90B | -2.53B | -1.41B | -183.00M | -484.00M | 2.06B | 70.00M | -2.50B | -1.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.56B | 33.18B | 34.40B | 34.42B | 33.53B | 33.32B | 31.97B | 29.04B | 30.25B | 30.45B | 30.01B | 28.53B | 28.52B | 26.27B | 26.97B | 29.25B | 28.13B | 24.56B | 23.19B | 21.06B | 18.82B | 16.17B | 15.58B | 15.32B | 14.55B | 12.42B | 11.92B | 11.31B | 9.95B | 8.35B | 7.57B | 7.36B | 6.57B | 5.78B | 5.03B | 4.70B | 4.20B | 3.66B | 3.24B |
| Cost & Expenses | 61.81B | 57.78B | 57.80B | 62.85B | 61.09B | 60.41B | 57.33B | 50.73B | 51.79B | 53.19B | 52.36B | 50.19B | 48.88B | 45.06B | 45.42B | 47.76B | 45.88B | 39.62B | 37.14B | 34.49B | 30.99B | 26.62B | 25.12B | 22.66B | 21.55B | 18.61B | 18.01B | 17.32B | 15.33B | 12.93B | 11.74B | 11.48B | 10.28B | 9.24B | 8.10B | 7.60B | 6.80B | 6.02B | 5.58B |
| Interest Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M | 385.00M | 368.00M | 128.00M | 67.00M | 74.00M | 64.00M | 91.00M | 107.00M | 90.00M | 361.00M | 452.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.01B | 934.00M | 726.00M | 552.00M | 533.00M | 482.00M | 532.00M | 571.00M | 348.00M | 451.00M | 435.00M | 296.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.52B | 1.44B | 1.25B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M | 391.00M | 356.00M | 275.20M | 250.50M |
| EBITDA | 23.73B | 27.17B | 30.93B | 27.50B | 28.27B | 28.10B | 24.54B | 24.92B | 22.12B | 25.03B | 23.16B | 17.96B | 16.05B | 20.35B | 18.96B | 20.20B | 16.36B | 15.77B | 15.61B | 15.02B | 13.27B | 11.82B | 9.78B | 8.08B | 7.59B | 6.96B | 5.62B | 5.46B | 4.42B | 3.58B | 2.93B | 2.78B | 2.65B | 2.63B | 2.08B | 1.70B | 1.47B | 1.79B | 985.40M |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% | 27.64% | 25.95% | 30.16% | 27.15% | 28.68% | 27.40% | 27.07% | 29.93% | 26.84% | 27.51% | 27.84% | 32.86% | 29.58% | 30.91% | 31.72% | 31.71% | 32.57% | 29.63% | 27.73% | 27.64% | 29.41% | 24.81% | 25.24% | 23.45% | 22.72% | 20.73% | 20.24% | 21.32% | 23.45% | 21.33% | 18.88% | 18.29% | 25.50% | 15.35% |
| Operating Income | 23.41B | 23.19B | 20.47B | 16.95B | 15.12B | 15.62B | 14.20B | 17.93B | 15.28B | 17.42B | 15.43B | 14.53B | 16.31B | 13.59B | 14.26B | 14.92B | 17.30B | 13.60B | 13.52B | 12.90B | 11.40B | 10.16B | 8.18B | 6.57B | 6.15B | 5.71B | 4.55B | 4.45B | 3.56B | 2.85B | 2.31B | 2.22B | 2.16B | 2.16B | 1.67B | 1.31B | 1.11B | 1.51B | 734.90M |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% | 19.15% | 18.57% | 24.94% | 21.80% | 23.44% | 21.64% | 21.61% | 25.08% | 22.06% | 23.03% | 23.40% | 28.31% | 25.50% | 26.76% | 27.24% | 27.24% | 27.99% | 24.77% | 22.53% | 22.38% | 24.14% | 20.10% | 20.57% | 18.90% | 18.12% | 16.37% | 16.16% | 17.36% | 19.23% | 17.09% | 14.53% | 13.84% | 21.57% | 11.44% |
| Total Other Income/Expenses | -8.35B | -2.85B | -1.77B | -3.24B | 2.21B | 2.38B | -1.22B | -1.09B | 907.00M | -574.00M | 38.00M | -3.26B | -3.79B | 420.00M | -908.00M | 760.00M | -1.93B | 990.00M | 137.00M | 482.00M | -563.00M | -387.00M | -277.00M | 303.00M | -108.00M | -846.00M | -46.00M | -270.00M | -194.00M | -126.00M | -62.00M | -70.00M | -126.00M | -369.00M | -147.00M | -8.00M | -16.00M | -592.80M | 164.30M |
| Income Before Tax | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B | 19.20B | 20.56B | 15.47B | 13.78B | 12.36B | 16.95B | 15.76B | 16.93B | 13.28B | 14.59B | 13.66B | 12.84B | 10.31B | 9.29B | 7.90B | 6.62B | 5.75B | 4.27B | 4.58B | 4.03B | 3.32B | 2.68B | 2.33B | 2.21B | 2.04B | 1.62B | 1.51B | 1.40B | 1.19B | 390.80M | 899.20M |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% | 22.06% | 23.12% | 27.55% | 27.39% | 27.66% | 21.69% | 20.49% | 19.01% | 27.52% | 25.45% | 26.56% | 21.74% | 27.36% | 27.03% | 27.11% | 24.62% | 25.60% | 23.93% | 22.73% | 20.94% | 18.05% | 20.22% | 18.65% | 17.60% | 17.04% | 16.49% | 16.05% | 16.37% | 14.45% | 15.52% | 15.51% | 14.89% | 5.58% | 14.00% |
| Income Tax Expense | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B | 3.79B | 4.24B | 1.64B | 3.26B | 2.69B | 3.61B | 3.49B | 3.98B | 2.71B | 3.53B | 3.25B | 4.33B | 3.11B | 2.69B | 2.23B | 1.82B | 1.59B | 1.21B | 1.27B | 1.15B | 914.00M | 675.00M | 545.00M | 582.00M | 577.00M | 480.00M | 432.00M | 422.00M | 360.00M | 61.30M | 285.50M |
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.85B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.41B | 8.51B | 7.20B | 6.60B | 5.67B | 4.80B | 4.17B | 3.06B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.03B | 1.46B | 1.14B | 1.08B | 974.00M | 833.00M | 329.50M | 613.70M |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% | 20.73% | 20.61% | 17.97% | 17.19% | 18.17% | 17.17% | 16.47% | 15.17% | 12.93% | 14.60% | 13.35% | 12.75% | 12.75% | 12.64% | 7.49% | 11.74% | 10.18% | 11.09% | 10.82% | 10.40% | 4.71% | 9.56% |
| EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 | 4.90 | 3.91 | 3.54 | 4.86 | 4.45 | 4.67 | 3.67 | 3.76 | 3.38 | 2.75 | 2.42 | 2.20 | 1.87 | 1.65 | 1.43 | 1.08 | 1.24 | 1.09 | 0.93 | 0.78 | 0.69 | 0.17 | 0.55 | 0.43 | 0.41 | 0.36 | 0.31 | 0.12 | 0.21 |
| EPS Diluted | 13.73 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 | 3.73 | 3.35 | 2.74 | 2.29 | 2.16 | 1.84 | 1.61 | 1.39 | 1.06 | 1.21 | 1.09 | 0.93 | 0.78 | 0.68 | 0.16 | 0.54 | 0.43 | 0.40 | 0.35 | 0.31 | 0.12 | 0.21 |
| Weighted Avg Shares Out | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B | 2.66B | 2.68B | 2.71B | 2.76B | 2.78B | 2.82B | 2.78B | 2.72B | 2.74B | 2.76B | 2.81B | 2.88B | 2.94B | 2.98B | 2.97B | 2.97B | 3.00B | 3.03B | 2.99B | 2.99B | 2.78B | 2.67B | 2.66B | 2.58B | 2.57B | 2.61B | 2.63B | 2.66B | 2.66B | 2.67B | 2.74B | 2.73B | 2.75B | 2.92B |
| Weighted Avg Shares Out (Dil) | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B | 2.96B | 3.00B | 2.99B | 3.14B | 3.05B | 3.08B | 3.10B | 3.07B | 2.83B | 2.74B | 2.73B | 2.58B | 2.61B | 2.63B | 2.63B | 2.71B | 2.69B | 2.71B | 2.78B | 2.73B | 2.75B | 2.92B |
Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View
Recent market concerns have pressured the stock prices of both Johnson & Johnson and Amgen Inc. In times of uncertainties, I go back to timeless insights like those offered by Peter Lync on dividend stocks. These insights led me to...
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.
Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this ideal. Analysts forecast 11.36% to 31.73%...
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis SPRING HOUSE, Pa. , Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications...
U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab)
BRIDGEWATER, N.J. and BENGALURU, India , Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA)...
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Forget Big Tech - I'll Take Dividend Stalwarts Any Day
Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SCHD ETFs, have matched or beat tech returns since 2021, fueled...
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa...
Source: https://incomestatements.info
Category: Stock Reports